Paper Review Records
全部论文审稿周期
24 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
43
天
Comparative bioavailability of a novel fixed‐dose combination of ticagrelor and acetylsalicylic acid
作者
Susana Tera‐Ponce; Perla E. Castañeda‐Tera; Elva J. García‐Real; Francisco Ávila‐García; Kevin F. Rios‐Brito; Laura A. Lugo‐Sánchez; Daniel E. Sandoval‐Colin; Paola M. Medina‐Cárdenas; Jorge González‐Canudas展开收起
作者单位
1. Department of Pharmacology Faculty of Medicine National Autonomous University of Mexico (UNAM) Mexico City Mexico; 2. Unidad Clínica Farmacológica Bioemagno S. A. de C. V Mexico City Mexico; 3. Bioanalit Laboratorios S.A. de C.V Mexico City Mexico; 4. Research and Development Department Laboratorios Silanes S.A. de C.V. Mexico City Mexico; 5. Mexican Social Security Institute (IMSS) Centro Médico Nacional Siglo XXI Mexico City Mexico展开收起
73
天
Pharmacokinetics and Bioequivalence of Tamsulosin Hydrochloride Extended‐Release Capsules in Healthy Chinese Volunteers: A Randomized, Open‐Label, Crossover Study Under Fasting and Fed Conditions
作者
Lijie Du; Xiaolu Wang; Yi Zhang; Jiamin Yang; Fangliang Gan; Yaxun Pang展开收起
作者单位
1. School of Pharmacy Hubei University of Science and Technology Xianning China; 2. Phase I Clinical Research Center Xianning Central Hospital The First Affiliated Hospital of Hubei University of Science and Technology Xianning China; 3. Department of Neurosurgery Xianning Central Hospital The First Affiliated Hospital of Hubei University of Science and Technology Xianning China展开收起
98
天
Pharmacokinetics and Bioequivalence Study of Levodopa and Benserazide Tablets in Healthy Chinese Subjects Under Fasting and High‐Fat Meal Conditions
作者
Yufei Liang; Yanchao Wang; Rui Shi; Yingzi Pei; Xiao Zhao; Qian Wang; Yanping Ren; Zekang Xie; Kexin Zhao展开收起
作者单位
1. Phase I Clinical Trials Center Hebei PetroChina Central Hospital Langfang China; 2. Department of Clinical Research Beijing Foyou Pharmaceutical Co., Ltd. Beijing China展开收起
119
天
Bioequivalence of Two Firsekibart Subcutaneous Formulations: A Randomized, Double‐Blind, Single‐Dose, Parallel‐Group Study in Healthy Chinese Participants
作者
Yehua Xie; Xiao Li; Yushi Chen; Guangli Ma; Fei Gu; Yuling Lian; Xu Zhang; Xiaolan Yong展开收起
作者单位
1. Changchun GeneScience Pharmaceutical Co., Ltd. Shanghai China; 2. Phase I Clinical Trial Center Chengdu Xinhua Hospital Chengdu China展开收起
152
天
Comparison of ABBV‐552 Safety and Pharmacokinetics in Healthy Asian and Western Adults
作者
Nick Miles; Brian McNamee; Cindy Zadikoff; Joey Boiser; Mohamad Shebley; Ramesh Boinpally展开收起
作者单位
1. Clinical Pharmacology AbbVie Inc. North Chicago IL USA; 2. Clinical Development Neuroscience AbbVie Inc. North Chicago IL USA; 3. Pharmacovigilance and Patient Safety AbbVie Inc. North Chicago IL USA展开收起
56
天
A Phase 1 Study to Assess the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate‐Release Tablet in Healthy Adults
作者
Michael J. Hanley; Ronald Gounden; Bradley Hupf; Saurabh Sarkar; Robert J. Fram; Neeraj Gupta展开收起
作者单位
1. Takeda Development Center Americas, Inc. Cambridge MA USA展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天